Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Autoimmune Drug Reactions To Get Further FDA Research After Ziagen Side Effect Findings

This article was originally published in The Pink Sheet Daily

Executive Summary

Carriers of the HLAB*57:01 allele who take Ziagen can come down with severe autoimmune reactions due to a mechanism traced by agency researchers.

You may also be interested in...



Targeted Therapies Have Most Clinically Useful Biomarker Labeling

Pharmacogenetic biomarkers for molecularly targeted therapies are supported by considerably better evidence that they improve patient outcomes than biomarkers in labeling of untargeted drugs, but a JAMA study still found that half of biomarkers in label lacked convincing evidence of clinical utility.

GSK’s Ziagen Relabeled: REMS And The Path To Personalized Medicine

A relabeling of GlaxoSmithKline's HIV treatment Ziagen (abacavir sulfate) to recommend pharmacogenomic screening illustrates the potential for FDA's new drug safety tools to encourage the push towards personalized medicine

Outlook 2023: Market Experts On Importance Of Value, Mental Health In A ‘World On Fire’

Competitive value propositions are a must in 2023 to win guarded consumers’ business. Companies that effectively address mental health and wellbeing needs and appeal to consumers through sustainability initiatives could have an edge in the recessionary environment, experts suggest. Meanwhile, there are concerns about small cosmetics companies and the availability of resources to help them comply with "modernized" federal regulations.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS074159

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel